An Industrial Policy and International Competitiveness in the Pharmaceutical Industry
DOI:
https://doi.org/10.33687/3v272r86Keywords:
: Industrial Policy, International Competitiveness, Pharmaceutical Industry, Innovation, Intellectual Property Rights, Trade Agreements, Global Value Chains, Public-Private Partnerships, Policy Frameworks, Economic GrowthAbstract
The pharmaceutical industry is a cornerstone of world Health systems and an essential driving force for financial increase and innovation. This paper explores the interaction between business coverage and international competitiveness inside the pharmaceutical area, specializing in how authorities' interventions form the industry's performance on an international scale. Commercial guidelines, together with studies of incentives, tax advantages, regulatory frameworks, and public-private partnerships, are vital levers that have an impact on the trajectory of pharmaceutical innovation and production. By way of analyzing case research from leading and emerging economies, this look identifies satisfactory practices and capability pitfalls in fostering an aggressive pharmaceutical region.
A key emphasis is located on the stability of supporting home production skills and integrating into worldwide price chains. The position of intellectual assets rights (IPR) is also scrutinized, highlighting its dual impact: fostering innovation through safety and probably hindering marketplace entry in growing international locations. Moreover, the paper evaluates the consequences of alternate agreements, investment techniques, and generation transfers at the enterprise's international positioning.
In a hastily evolving global landscape shaped by technological advances, pandemics, and shifting geopolitical dynamics, the pharmaceutical enterprise faces developing challenges and possibilities. This research underscores the importance of coherent and adaptive commercial policies that prioritize sustainability, accessibility, and resilience at the same time as improving worldwide competitiveness.
In the long run, this study contributes to the wider discourse on how strategic policy frameworks can bolster the pharmaceutical industry's potential to innovate, compete, and meet international fitness demands.
Downloads
References
1Barney, Jay B. “Firm Assets and Sustained Aggressive Advantage.” journal of Management 17, no. 1 (1991): 99–120
2Burstall, Margaret L. The Society's Drug Manufacturing. Luxembourg: workplace for legitimate guides of the ecu groups, 1985.
3Council of Economic Advisers. Monetary report of the President, 1984. Washington, DC: authorities printing workplace, 1984.
4Chandler, Alfred. Scale and Scope: The Dynamics of Business Capitalism. Cambridge, MA: Harvard University Press, 1990.
5Freeman, Elizabeth. Era, policy, and monetary overall performance. London: Francis Pinter, 1987.
6Johnson, Chalmers, Laura D’Andrea Tyson, and John Zysman, eds. Politics and productivity: How Japan’s development method Works. NY: HarperCollins, 1989.
7Kuttner, Robert. The financial illusion. Boston: Houghton Mifflin, 1984.
8Lawrence, Robert Z. Can the United States Compete? Washington, DC: Brookings group, 1984.
9Levin, Richard C., Alvin ok. Klevorick, Richard R. Nelson, and Sidney G. Winter. “Appropriating the Returns from business studies and improvement.” Brookings Papers on financial pastime, no. Microeconomics (1987): 783–832.
10Nelson, Richard R. Countrywide Innovation systems: A Comparative analysis. Oxford: Oxford University Press, 1993.
11Porter, Michael E. The competitive gain of countries. The big apple: loose Press, 1990.
12Brief, Peter D. “commercial enterprise: Reagan’s commercial policy.” in the Reagan file: An assessment of the US’s changing home Priorities, edited with the aid of John L. Palmer and Isabel V. Sawhill. Cambridge, MA: Ballinger, 1984.
13Reich, Robert B. The Next American Frontier. NY: Penguin Books, 1983.
14Reich, Robert B. “Bailout.” Yale magazine on law 2 (1985): 163–224.
15Rumelt, Richard P. “towards a Strategic principle of the firm.” In competitive Strategic management, edited by using David J. Teece. Englewood Cliffs, NJ: Prentice-hall, 1984.
16Schultze, Charles L. “commercial policy: A Dissent.” Brookings evaluation, Fall 1983, three–12.
17Teece, David J. “benefiting from Technological Innovation: Implications for Integration, Collaboration, Licensing, and Public policy.” Studies Policy 15, no. 6 (December 1986): 285–305.
18Teece, David J., Richard P. Rumelt, Giovanni Dosi, and Sidney G. Wintry Weather. “Understanding Corporate Coherence: idea and proof.” running paper, 1992.
19Thomas, L. G. “Implicit commercial policy: The Triumph of England and the Failure of France in global prescription drugs.” commercial and Company Trade Three, no. 1 (1994): 45–81.
20Thomas, L. G. “regulation and company size: FDA influences on Innovation.” RAND Journal of Economics 21, no. 4 (1990): 497–517.
21Thomas, L. G. “Spare the Rod and break the industry: commercial organization and opposition.” operating paper, Emory University, 1992.
22Weidenbaum, Murray. Rendezvous with truth: the American economy after Reagan. New York: simple Books, 1988.
23Wernerfelt, Birger. “An aid-based View of the company.” Strategic Management magazine 5, no. 2 (April–June 1984): 171–eighty.
24Zysman, John, and Laura D’Andrea Tyson, eds. American enterprise in global competition: authority’s guidelines and company strategies. Ithaca, New York: Cornell University Press, 1983.
Published
Data Availability Statement
The authors confirm that all data generated or analyzed during this study are included in this published article. Additionally, the research data have been made available in a public repository at [Figshare], allowing for transparency and reproducibility of the findings.
Issue
Section
Categories
License
Copyright (c) 2025 Rehan Naqvi, Geetha Kumari Das, Sambreen Zameer, Zameer Ahmed
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
